Gonadotropin-releasing hormone treatment may protect against testicular tumor development by downregulating oncogenes, such as MALAT1, mTOR, C-MYC, and EZH2 to enable normal germ cell development. This evidence concerns the gene EZH2 and neoplasm of testis.